CA-GLOBALLOGIC
5.5.2021 14:32:06 CEST | Business Wire | Press release
GlobalLogic Inc. , a leader in Digital Product Engineering, today announced it has earned the Kubernetes on Microsoft Azure advanced specialization, a validation of a solution partner’s deep knowledge, extensive experience and proven expertise in deploying and managing production workloads in the cloud using containers and managing hosted Kubernetes environments in Microsoft Azure. GlobalLogic pursued this particular capability to keep in step with its customers’ growing need for a robust, scalable container orchestration system capable of supporting their digital transformation journeys.
Only partners that meet stringent criteria around customer success and staff skilling, as well as pass a third-party audit of their container-based workload deployment and management practices, are able to earn the Kubernetes on Azure advanced specialization.
With over 75% of global organizations expected to run containerized applications in production by 2022, many are looking for a partner with advanced skills to migrate their existing containerized workloads to the cloud or assist them in developing cloud-native applications using container technologies, DevOps patterns, and a microservices approach.
Kubernetes is a portable, extensible, open-source platform for managing containerized workloads and services across virtual machines. It facilitates both declarative configuration and automation while optimizing required compute power. Collectively, these features are known to simplify cloud migration, shorten software development cycles, and reduce cloud costs among other benefits.
Overseen by the Cloud Native Computing Foundation (CNCF), Kubernetes is growing rapidly in popularity. In March 2020, the organization released its 2019 survey results assessing cloud native adoption trends according to more than 1300 respondents. Container use itself in 2019 increased to 84 percent—a 15 percent jump from 2018. Importantly, 78 percent of respondents are using Kubernetes in production.
“Sophisticated container orchestration is a necessary function to modern, digital business models—particularly as a computing tool that we can smartly pair with microservice architectures for stronger platform optimization,” said Raja Renganathan, SVP and GM, Cloud Engineering, GlobalLogic. “The clear benefits of Kubernetes in a Microsoft Azure environment is increasingly important as we help global brands quickly design, develop and bring to market engaging new products and services that promise new revenue streams.”
Rodney Clark, Corporate Vice President, Global Partner Solutions, Channel Sales and Channel Chief at Microsoft, added, “The Kubernetes on Microsoft Azure advanced specialization highlights the partners who can be viewed as most capable when it comes to deploying and managing containerized applications in Azure. GlobalLogic clearly demonstrated that they have both the skills and the experience to deliver best-in-class cloud-native capabilities to customers with Azure.
Useful Links
GlobalLogic: http://www.globallogic.com
LinkedIn: https://www.linkedin.com/company/globallogic/
Facebook: https://www.facebook.com/GlobalLogic/
Twitter: https://twitter.com/GlobalLogic
About GlobalLogic
GlobalLogic (www.globallogic.com ) is a leader in digital product engineering. We help our clients design and build innovative products, platforms, and digital experiences for the modern world. By integrating strategic design, complex engineering, and vertical industry expertise—we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the communications, financial services, automotive, healthcare, technology, media and entertainment, manufacturing, and semiconductor industries.
GlobalLogic is a trademark of GlobalLogic. All other brands, products or service names are or may be trademarks or service marks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210505005148/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom